865756-07-6

Basic information

• Product Name: 6-(2,6-dichlorophenyl)-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one
• Synonyms: 6-(2,6-dichlorophenyl)-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one
• CAS NO: 865756-07-6
• Molecular Weight: 338.217
• Mol File: 865756-07-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 6-(2,6-dichlorophenyl)-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(2,6-dichlorophenyl)-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one(865756-07-6)
• EPA Substance Registry System: 6-(2,6-dichlorophenyl)-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one(865756-07-6)

Safety Data

• Hazardous Substances Data: 865756-07-6(Hazardous Substances Data)

Upstream product

• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 588-36-3 (4-amino-2-(methylthio)pyrimidin-5-yl)methanol 
• 776-53-4 ethyl 4-amino-2-methylmercaptopyrimidine-5-carboxylate 
• 770-31-0 4-amino-2-(methylthio)pyrimidine-5-carbaldehyde 
• 54551-83-6 methyl 2-(2,6-dichlorophenyl)acetate 
• 179343-52-3 6-(2,6-dichlorophenyl)-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-amine 
• 3215-64-3 2,6-dichlorophenylacetonitrile 
• 6575-24-2 2-(2,6-dichlorophenyl)acetic acid 

Downstream Products

• 865756-08-7 trifluoro-methanesulfonic acid 6-(2,6-dichloro-phenyl)-2-methylsulfanyl-pyrido[2,3-d]pyrimidin-7-yl ester 

Relevant articles and documents

Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling

Receptor interacting protein kinase-2 (RIPK2) is an enzyme involved in the transduction of pro-inflammatory nucleotide-binding oligomerization domain (NOD) cell signaling, a pathway implicated in numerous chronic inflammatory conditions. Herein, a pyrido[

Optimization and Mechanistic Characterization of Pyridopyrimidine Inhibitors of Bacterial Biotin Carboxylase

A major challenge for new antibiotic discovery is predicting the physicochemical properties that enable small molecules to permeate Gram-negative bacterial membranes. We have applied physicochemical lessons from previous work to redesign and improve the antibacterial potency of pyridopyrimidine inhibitors of biotin carboxylase (BC) by up to 64-fold and 16-fold against Escherichia coli and Pseudomonas aeruginosa, respectively. Antibacterial and enzyme potency assessments in the presence of an outer membrane-permeabilizing agent or in efflux-compromised strains indicate that penetration and efflux properties of many redesigned BC inhibitors could be improved to various extents. Spontaneous resistance to the improved pyridopyrimidine inhibitors in P. aeruginosa occurs at very low frequencies between 10-8 and 10-9. However, resistant isolates had alarmingly high minimum inhibitory concentration shifts (16- to >128-fold) compared to the parent strain. Whole-genome sequencing of resistant isolates revealed that either BC target mutations or efflux pump overexpression can lead to the development of high-level resistance.

6-PHENYLPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS AS ANTIBACTERIAL AGENTS

The disclosure relates to antibacterial compounds having the Formula (I), where R1, R2, R3, R4, R8, n, and p are described herein, as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, pharmaceutical compositions comprising such compounds, methods of treating bacterial infections by the administration of such compounds, and processes for the preparation of the compounds.